Biotheryx
Financial Services · Health Care
$92.1Mlatest round · Venture round · May 2021 · 5 yr ago
2backers · Lumira Ventures, SR One
17team · US Form 5500 (plan participants) · Dec 2025 · -6% in a year
20stories in the press
Overview
Degrading proteins.Saving lives.. Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on validated targets in cancer and inflammatory disease.
Funding and backers
Total raised
$92.1M
1 round on record
Latest round
$92.1M
Venture round · May 2021 · 5 yr ago
Team
17
US Form 5500 (plan participants) · Dec 2025 · -6% in a year
Backers
2
Lumira Ventures, SR One
The money's age
Long since its last round
65 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 7, 2024
Certified Biotheryx Announces U.S. FDA Clearance of Investigational New Drug Application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4/6 · biotheryx.com
Feb 23, 2022
Board appointment BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directors · PRNewswire
May 19, 2021
Raised a round Venture round $92.1M · SEC Form D
Nov 11, 2019
Board appointment BioTheryX, Inc. Announces the Appointment of BioPharma Finance Veteran Peter N. Crnkovich to Board of Directors · wfmz.com
Sep 17, 2019
Board appointment BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors · medindia.net
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2021 | $92.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | BIOTHERYX, INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kyle ChanExecutive OfficerSEC Form D
Dung ThaiExecutive OfficerSEC Form D
Jaime DonadioExecutive OfficerSEC Form D
David StirlingExecutive Officer, DirectorSEC Form D
Frank MercurioExecutive OfficerSEC Form D
Robert WilliamsonExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Maxion Therapeutics
backs QuantX Biosciences
Similar startupsby what they do, their industry and backers
Magnet Biomedicine is advancing monovalent molecular glue inhibitors (MGIs) and innovative protein degraders to engage disease drivers.
AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
Maxion Therapeutics | We are using our revolutionary KnotBody® technology to create first-in-class and best-in-class protein therapeutics…
Transforming the Future of Neuropsychiatry. Draig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to…
Pioneering the development of cell-specific, targeted protein degraders with the precision of antibody targeting.
At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in…
Financials
Total raised
$92.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $92.1M | Details |
People
Kyle Chan
Executive Officer
Dung Thai
Executive Officer
Jaime Donadio
Executive Officer
David Stirling
Executive Officer, Director
Frank Mercurio
Executive Officer
Robert Williamson
Executive Officer, Director
Jack Noelke
Director
Christopher Devine
Director
Louis DeGennaro
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
SR OneVia a fund
Lumira VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer
San Diego, CA, May 18, 2026 - Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced the data from its first-in-human Phase 1 Dose Esc
Read more
Report
Biotheryx to Present Results from its Phase 1A Dose Escalation Study of BTX-9341 for the Treatment of HR+/HER2- Breast Cancer at the 2026 European Society for Medical Oncology Breast Cancer Annual Congress
SAN DIEGO, CA, May 4, 2026 - Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that data from its Phase 1A Dose Escalation Study
Read more
Report
Biotheryx to Present Results from its Phase 1A Dose Escalation Study of BTX-9341 for the Treatment of HR+/HER2- Breast Cancer at the 2026 European Society for Medical Oncology Breast Cancer Annual Congress
Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that data from its Phase 1A Dose Escalation Study of BTX-9341, a potent and sel
Read more
Report
Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer
SAN DIEGO, CA, March 18, 2026 - Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced that the first patient has been dosed in the do
Read more
Report
Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer
Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, today announced the completion of enrollment in the ongoing Phase 1a clinical trial of BTX-9341
Read more
Report
Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment of HR+/HER2- Breast Cancer
Topline data readout from Phase 1a clinical trial expected in Q1 2026 SAN DIEGO, CA, November 17, 2025 - Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory
Read more
Report
Biotheryx and Incyte Expand Partnership to Discover Molecular Glue Degraders for Novel Targets
Partnership will continue to leverage Biotheryx's PRODEGY platform to discover molecular glue degraders for multiple historically undruggable novel targets Biotheryx will receive an undisclosed upfront payment and is eligible to receive up to $354 million
Read more
Report
Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer
SAN DIEGO, CA. July 17, 2024 - Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory diseases, today announced that the first pa
Read more
Report
Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with ...
Read more
Report
Biotheryx Announces U.S. FDA Clearance of Investigational New Drug Application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4/6
SAN DIEGO, CA. May 7, 2024 - Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced that the U.S. Food a
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego
United States
HQ
200-500 est. staff